| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
|
| | CD532 hydrochloride Basic information |
| Product Name: | CD532 hydrochloride | | Synonyms: | Urea, N-[4-[[4-[(5-cyclopentyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]phenyl]-N′-[3-(trifluoromethyl)phenyl]-, hydrochloride (1:1);CD532 hydrochloride;CD532 hcl | | CAS: | 2926498-81-7 | | MF: | C26H25F3N8O.ClH | | MW: | 558.99 | | EINECS: | | | Product Categories: | | | Mol File: | 2926498-81-7.mol |  |
| | CD532 hydrochloride Chemical Properties |
| form | Solid | | color | White to off-white |
| | CD532 hydrochloride Usage And Synthesis |
| Uses | CD532 hydrochloride is a potent Aurora A kinase inhibitor with an IC50 of 45 nM. CD532 hydrochloride has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 hydrochloride also can directly interact with AURKA and induces a global conformational shift. CD532 hydrochloride can be used for the research of cancer[1][2]. | | in vivo | | Animal Model: | Homozygous nu/nu mice with SHH-subtype MYCN-expressing medulloblastoma[1] | | Dosage: | 25 mg/kg | | Administration: | I.p. twice weekly for 3 weeks | | Result: | Decreased the level of MYCN protein and tumor volume and increases survival.
|
| | References | [1] Gustafson WC, et, al. Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell. 2014 Sep 8;26(3):414-427. DOI:10.1016/j.ccr.2014.07.015
[2] Lee JK, et, al. N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. Cancer Cell. 2016 Apr 11;29(4):536-547. DOI:10.1016/j.ccell.2016.03.001 |
| | CD532 hydrochloride Preparation Products And Raw materials |
|